Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Provectus Biopharmaceuticals Q3 2026 Results: Net Loss of $1.27M, Loss Narrows

Provectus Biopharmaceuticals reported a net loss of $3.56 million for the nine months ended September 30, 2026, compared to a $4.34 million loss in the prior year period. The company remains in the development stage with no revenue from drug candidates and is currently operating with a significant stockholders' deficit of $6.68 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-1.3-1.3
EPS (diluted, $ a share)$-0.00$-0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, OTC: PVCT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Provectus Biopharmaceuticals, Inc.: key numbers

Share price
$0.0459Close, Nov 16
Market cap
$19.3M
Shares outstanding
420.28MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.